Business Wire

CA-VERACODE

1.5.2024 14:51:32 CEST | Business Wire | Press release

Share
Veracode Elevates Developer-Powered Application Risk Management with Latest Innovations: Enhanced Repo Risk Visibility & Analysis and Veracode Fix in the IDE

Veracode, a global leader in application risk management, today announced platform innovations that set a new standard for developer-powered application security. New repo risk visibility and analysis from Longbow Security, powered by Veracode, speeds up remediation of application risk from code repositories to runtime images. The solution launches alongside Veracode Fix in the Integrated Development Environment (IDE) and Batch Fix to bridge the gap between development and security teams. These latest innovations help developers focus on the most critical tasks that drive value and differentiation.

“Developers today face significant competing pressures to innovate faster and perform more security checks on their code than ever before,” said Tim Jarrett, Group Head of Product Management at Veracode. “We are committed to a frictionless experience for developers and security operators and our latest product enhancements make the job of securing code simple and seamless.”

Bringing Developer & Security Teams Together: Repo Risk Visibility & Analysis

In April, Veracode acquired Longbow Security to help organizations effectively manage and reduce application risk across the growing attack surface. The integration of Longbow’s newest capability, repo risk visibility and analysis, bridges the gap between development and security teams with enhanced visibility from code repositories to cloud assets and runtime images. It also illuminates infrastructure-as-code and misconfiguration risk for cloud assets originating from repositories.

“Customers challenged us to apply our unique cloud risk and prioritization expertise from Longbow to problems they face managing upstream risk in their code repositories,” said Derek Maki, Vice President of Product Management at Veracode. “We responded with a solution that gives visibility into the relationship between source code weaknesses and runtime security posture. Simultaneously, development teams get a consolidated view of risk and huge time savings when it comes to prioritizing remediation, reducing code changes, and fixing issues fast.”

This new feature complements Veracode’s latest innovation for GitHub repo scanning, which enables developers to streamline activities like staging servers and environments so they don’t need to scan every time. This makes it easier for development and security teams to collaborate on secure coding and scanning as Veracode results are delivered to GitHub where developers can act immediately.

Security Debt Reduction: Veracode Fix in the IDE & Batch Fix

Research shows 92 percent of U.S.-based developers are already using artificial intelligence (AI) coding tools both in and outside of work, with generative AI helping software engineers write code 35-45 percent faster. At the same time, other research suggests code developed by AI contains the same percentage of security flaws as that generated by humans.

Veracode was the first company to deliver a solution that provides developers with AI-generated secure code fixes. Since launching Veracode Fix at RSA Conference last year, hundreds of customers have used the solution to reduce their backlog of security debt and risk. Ninety-two percent of CWEs (Common Weakness Enumeration) with a severity rating from medium to very high can be addressed through AI-generated code edits from Veracode Fix.

With the introduction of Veracode Fix in the IDE, developers can now fix flaws faster with AI-suggested remediation right in the IDE, without switching applications or researching alternative code options. Fixes can be made before code is pushed through the software development lifecycle, dramatically cutting the time and cost spent fixing flaws compared to retroactive remediation.

Batch Fix enables bulk AI-assisted remediation of flaws in source code across multiple flaws and files in one operation. This makes remediation of flaws an order of magnitude faster, aiding the reduction of security debt at scale. For example, developers can use it to fix a CWE that requires an easy-to-test resolution and run it across multiple source files at once.

Jarrett closed, “With these latest innovations, Veracode meets developers where they are—in the tools they use daily—to help them secure the code they create today, without compromising productivity. This vastly improves efficiency and velocity, fostering a culture of collaboration and trust between development and security teams.”

Repo Risk Visibility & Analysis, Veracode Fix in the IDE, and Batch Fix are available immediately. For more information, please visit the Veracode blog.

Visitors to RSA Conference can learn more about Veracode’s platform and these new features by visiting Veracode’s booth #2045 in the main hall.

About Veracode

Veracode is a global leader in Application Risk Management for the AI era. Powered by trillions of lines of code scans and a proprietary AI-assisted remediation engine, the Veracode platform is trusted by organizations worldwide to build and maintain secure software from code creation to cloud deployment. Thousands of the world’s leading development and security teams use Veracode every second of every day to get accurate, actionable visibility of exploitable risk, achieve real-time vulnerability remediation, and reduce their security debt at scale. Veracode is a multi-award-winning company offering capabilities to secure the entire software development life cycle, including Veracode Fix, Static Analysis, Dynamic Analysis, Software Composition Analysis, Container Security, Application Security Posture Management, and Penetration Testing.

Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and Twitter.

Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240501107223/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release

News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release

Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye